Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.
Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF, Daidone MG, Pierotti MA, Berns EM, Jansen MP, Foekens JA, Delorenzi M, Bontempi G, Piccart MJ, Sotiriou C. · 2008
Read Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. by Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF, Daidone MG, Pierotti MA, Berns EM, Jansen MP, Foekens JA, Delorenzi M, Bontempi G, Piccart MJ, Sotiriou C. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2423197.txt.
Introduction
Loi and a large team built a gene-based predictor for hormone-sensitive breast cancer in 2008. These cancers carry the estrogen receptor and are treated with tamoxifen, a hormone-blocking drug. Yet 30% to 40% of such patients relapse anyway, so better forecasting tools were needed.
They trained the predictor on 255 tumor samples from women treated with tamoxifen alone after surgery. The final classifier used 181 genes grouped into 13 clusters of genes that rise and fall together. Six clusters covered cell division pathways. In an independent set of 362 patients, the classifier split women into two outlook groups with a hazard ratio of 2.01 between them. In 112 patients with spread cancer, one cluster pointing to inflammation predicted who would respond to tamoxifen. The clusters aid reading the biology, not just the score.
Catalog record
| CREATOR | Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF, Daidone MG, Pierotti MA, Berns EM, Jansen MP, Foekens JA, Delorenzi M, Bontempi G, Piccart MJ, Sotiriou C. |
|---|---|
| YEAR | 2008 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen By Sherene Loi, Benjamin Haibe-Kains, Christine Desmedt, Pratyaksha Wirapati, Françoise Lallemand, Andrew M Tutt, Cheryl Gillet, Paul Ellis, Kenneth Ryder, James F Reid, Maria G Daidone, Marco A Pierotti Published in: BMC Genomics DOI: 10.1186/1471-2164-9-239 ABSTRACT Abstract Background Estrogen receptor positive (ER+) breast cancers (BC) are heterogeneous with regard to their clinical behavior and response to therapies. The ER is currently the best predictor of response to the anti-estrogen agent tamoxifen, yet up to 30–40% of ER+BC will relapse despite tamoxifen treatment. New prognostic biomarkers and further biological understanding of tamoxifen resistance are required. We used gene expression profiling to develop an outcome-based predictor using a training set of 255 ER+ BC samples from women treated with adjuvant tamoxifen monotherapy. We used clusters of highly correlated genes to develop our predictor to facilitate both signature stability and biological interpretation. Independent validation was performed using 362 tamoxifen-treated ER+ BC samples obtained from multiple institutions and treated with tamoxifen only in the adjuvant and metastatic settings. Results We developed a gene classifier consisting of 181 genes belonging to 13 biological clusters. In the independent set of adjuvantly-treated samples, it was able to define two distinct prognostic groups (HR 2.01 95%CI: 1.29–3.13; p = 0.002). Six of the 13 gene clusters represented pathways involved in cell cycle and proliferation. In 112 metastatic breast cancer patients treated with tamoxifen, one of the classifier components suggesting a cellular inflammatory mechanism was significantly predictive of response. Conclusion We have developed a gene classifier that can predict clinical outcome in tamoxifen-treated ER+ BC patients. Whilst our study emphasizes the important role of proliferation genes in prognosis, our approach proposes other genes and pathways that may elucidate further mechanisms that influence clinical outcome and prediction of response to tamoxifen. BACKGROUND Breast cancers are biologically heterogeneous with regards to their clinical behavior and response to therapies. However, treatment-decision making for women diagnosed with breast cancer is still reliant on classical histopathological appearance and immunohistochemical markers that give little insight into tumor biology and potential response to treatment. There are a few biomarkers routinely used that can predict response to commonly prescribed therapies. The presence of estrogen receptors is the best indicator of response to anti-estrogen agents such as tamoxifen. However, 30–40% of women with estrogen receptor-positive breast cancer (ER+BC) will develop distant metastases and die despite tamoxifen treatment. The underlying biological mechanisms of resistance to tamoxifen are incompletely understood. Gene expression profiling of tumors appears to be a promising new strategy for predicting clinical outcome in breast cancer patients. Recent studies have proposed that the heterogeneity of clinical response can be correlated with different molecular "portraits" [1,2]. Gene signatures have been developed that can distinguish subgroups of patients with different prognoses or response to chemotoxic and antiestrogen agents. However, issues have emerged since these initial studies relating to design and validation of gene classifiers [3], particularly the small numbers of patient samples used to derive the classifier and the little overlap in these gene signatures. Furthermore, it has been shown that membership in a prognostic gene list is not necessarily indicative of a gene's importance in cancer pathology [4]. Extracting biological meaning from whole genome molecular profiling remains a significant challenge. We have recently shown that in ER+ BC, its proliferative status is the most important predictor of prognosis in these women [5]: highly proliferative tumors have a worst clinical outcome, either with or without systemic treatment. However, proliferation is a downstream consequence and the understanding of the upstream activators is essential for advancing biological knowledge and development of targeted approaches that may be tested in the clinical setting, potentially in combination with anti-estrogen agents. In this study, we hypothesized that developing a gene classifier using clusters of correlated genes as single variables may allow for both prediction of clinical outcome in tamoxifen-treated patients and facilitate new biological understanding of resistance mechanisms as these clusters could represent biological networks or pathways. Furthermore, we assessed the performance of our classifier on several independent data sets of tamoxifen-treated samples, both in the adjuvant as well as advanced setting. These were obtained from a number of institutions and samples had been hybridized on varying microarray platforms. METHODS Tamoxifen-treated dataset used in development of the classifier The dataset used for training the classifier consisted of 255 early-stage (stage I, II) BC samples, diagnosed between 1980 and 1995, all of whom had received tamoxifen only as their adjuvant treatment (hereby referred to as the "tamoxifen-treated dataset"). The demographics can be found in [Additional file 1], and data processing methods are described in Loi et al. [6] as a large proportion of this dataset has been previously used in another research study. The raw data for the tamoxifen-treated dataset are available at the GEO database (accession number GSE6532). This dataset contained samples from the John Radcliffe Hospital (OXFT), Oxford, United Kingdom, Guys Hospital (GUYT), London, United Kingdom and Uppsala University Hospital (KIT), Uppsala, Sweden. All samples had been hybridized using Affymetrix U133 Genechips™ (HG-U133A, B for OXFT and KIT, and PLUS2 for GUYT). All samples were required to be estrogen (ER) and/or progesterone receptor (PR) positive by ligand-binding assay and had been prescribed tamoxifen monotherapy for 5 years post diagnosis as adjuvant therapy. The cut-off value for classification of patients as positive or negative for ER and PR was 10 fmol per mg protein. The primary endpoint used for generating the classifier was the first distant metastatic event (distant metastasis free survival, DMFS), as survival can be confounded by local recurrence and treatments given at relapse. Each hospital's institutional ethics board approved the use of the tissue material for the purposes of this research study. Statistical methods Figure 1a and 1b summarize the method used to develop the gene classifier. [Figure: Overview of the analysis design. (a) First part of the analysis including quality controls, normalization, preliminary clustering performed on the untreated dataset, computation of the cluster centroids on the tamoxifen treated dataset, and estimation of signature stability with regards to signature size, using cross-validation. (b) Second part of the analysis including the classifier development, performance assessment by cross-validation and performance assessment on independent validation data sets.] Preliminary clustering We used a clustering method in order to identify clusters of highly correlated genes, prior to feature selection and model building as we hypothesized that this would to reduce the number of variables, increase signature stability, allow platform independency and to preserve biological interpretation [8]. Preliminary clustering was performed on separate dataset consisting of 137 samples from untreated women with early stage breast cancer (data available from GEO database, accession number GSE6532). These samples were not used in the signature development to avoid any possible overfitting when performing the cluster identification. Control probe sets and those absent in at least 95% of the samples were removed. The data set was then filtered based on overall variance with the top 20% of probe sets selected for further clustering. Hierarchical clustering with Pearson correlation similarity metric and complete linkage was used. The generated dendrogram was then cut at a height of 0.5. Clusters were discarded if there were less than 5 known genes (as per